Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+8.23%
+2.03%
-1.03%
-5.50%
INSM
Insmed
$105.42
Chart
$65.63 (+60.63%)
$76.57 (+37.68%)
$76.57 (+37.68%)
$70 (+50.60%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+8.23%
+2.03%
-1.03%
-5.50%
INSM
Insmed
Current Price
$105.42
Login to view Insmed (INSM) recommendation from the last 90 days from financial news and social media.
Chart
$65.63 (+60.63%)
$76.57 (+37.68%)
$76.57 (+37.68%)
$70 (+50.60%)
INSM Latest Analysis
Mizuho Reiterates Outperform Rating on Insmed (INSM) Boosts PT to $110.
Wed Jun 18, 2025
Wells Fargo Lifts Price Target on Insmed Incorporated (INSM) to $119 From $107.
Tue Jun 17, 2025
Is Insmed Stock Overvalued at $98?. Insmed Inc (NASDAQ: INSM) was nothing short of a juggernaut last month skyrocketing 45% while the S&.P500 index gained 3% during the same period. What&rsquo.s fueling the fire? Insmed announced that its Phase .IIb trial for treprostinil palmitil inhalation powder (TPIP) in pulmonar
Tue Jun 17, 2025
Insmed prices capital raise of $750 via stock offering.
Thu Jun 12, 2025
INSM Crosses Above Average Analyst Target. In recent trading shares of Insmed Inc (Symbol: INSM) have crossed above the average analyst 12-month target price of $97.70 changing hands for $97.98/share. When a stock reaches the target an analyst has set the analyst logically has two ways to react: downgrade on valuation
Thu Jun 12, 2025
$100 Invested In Insmed 10 Years Ago Would Be Worth This Much Today. Insmed (NASDAQ:) has outperformed the market over the past 10 years by 4.43% on an annualized basis producing an average annual return of 15.51%. Currently Insmed has a market capitalization of $17.70 billion.
Wed Jun 11, 2025
Insmed announces $650M public offering of common stock.
Wed Jun 11, 2025
Insmeds Pulmonary Hypertension Drug Data Exceeded Even ish Outlook Analysts Boost Price Forecast. ) on Tuesday released topline results from its Phase2bstudy of treprostinil palmitil inhalation powder (TPIP) administered once daily in patients with .The study met its primary endpoint and all secondary efficacy endpoints. For the primary endpoint the placebo-adjusted reduction from baseline in pulmonary vascular resistance (PVR) was 35% with a Least Squares (LS).The placebo-adjusted improvement i
Wed Jun 11, 2025
Insmed stock soars to 52-week high touches $92.35.
Wed Jun 11, 2025
Wall Street ends higher as investors track US-China trade talks . The S&.P 500 closed higher boosted by Teslas surge. Investors were optimistic about United States-China trade discussions. Wall Street anticipated improved trade terms. Energy and consumer discretionary sectors led the gains. Investors are awaiting United States consumer prices data. The World Bank reduced its global growth forecast. Insmed shares rose on positive drug trial results. J.M.
Tue Jun 10, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
INSM Stock trends
INSM Stock performance
INSM Stock analysis
INSM investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
